Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Sees Large Increase in Short Interest

Key Points

• Damora Therapeutics saw a 35.0% increase in short interest in April to 1,116,620 shares (about 2.1% of shares sold short), with a days‑to‑cover ratio of 4.7.
• Shares traded down 5.0% to $24.23 on Tuesday; the company has a market capitalization of $1.46 billion, a 12‑month range of $2.45–$38.33, and a negative P/E of -2.00.
• Analyst coverage is mixed but skewed positive—MarketBeat shows an average rating of Moderate Buy and an average target of $43.40—and institutional/hedge funds own roughly 14.2% after several recent new stakes.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) saw a large increase in short interest during the month of April. As of April 15th, there was short interest totaling 1,116,620 shares, an increase of 35.0% from the March 31st total of 827,221 shares. Currently, 2.1% of the company's shares are sold short. Based on an average daily volume of 236,386 shares, the days-to-cover ratio is currently 4.7 days.

Damora Therapeutics, Inc. Common Stock Stock Down 5.0%

Shares of NASDAQ DMRA traded down $1.27 during trading on Tuesday, reaching $24.23. 111,691 shares of the stock were exchanged, compared to its average volume of 237,441. The business's 50-day moving average price is $26.97 and its 200 day moving average price is $22.95. Damora Therapeutics, Inc. Common Stock has a twelve month low of $2.45 and a twelve month high of $38.33. The company has a market capitalization of $1.46 billion, a price-to-earnings ratio of -2.00 and a beta of 1.59.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on DMRA shares. Weiss Ratings reiterated a "sell (e+)" rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, December 29th. Royal Bank Of Canada started coverage on Damora Therapeutics, Inc. Common Stock in a report on Friday. They issued an "outperform" rating and a $40.00 target price on the stock. Zacks Research upgraded Damora Therapeutics, Inc. Common Stock to a "hold" rating in a report on Friday, January 9th. Evercore started coverage on Damora Therapeutics, Inc. Common Stock in a report on Wednesday, March 25th. They issued an "outperform" rating and a $46.00 target price on the stock. Finally, Leerink Partners began coverage on Damora Therapeutics, Inc. Common Stock in a report on Wednesday, January 7th. They issued an "outperform" rating and a $46.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $43.40.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DMRA. Ikarian Capital LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at about $6,574,000. Jain Global LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth about $2,774,000. Remedium Capital Partners LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth about $2,772,000. Boothbay Fund Management LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth about $2,204,000. Finally, Geode Capital Management LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth about $266,000. 14.20% of the stock is owned by hedge funds and other institutional investors.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company's research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.